6533b873fe1ef96bd12d5965
RESEARCH PRODUCT
Thyroid hormone controls carnitine status through modifications of gamma-butyrobetaine hydroxylase activity and gene expression.
Béatrice GeorgesJean DemarquoyF. Le BorgneStéphane GallandJ. Viana DiasGregory Conductiersubject
Maleendocrine systemmedicine.medical_specialtyThyroid Hormonesendocrine system diseasesgamma-Butyrobetaine DioxygenaseThyroid GlandBiologyGene Expression Regulation EnzymologicMixed Function OxygenasesCellular and Molecular Neurosciencechemistry.chemical_compoundInternal medicineCarnitinemedicineAnimalsCarnitineRNA MessengerMolecular BiologyBeta oxidationPharmacologychemistry.chemical_classificationFatty acid metabolismThyroidFatty acidLipid metabolismCell BiologyRatsKineticsEndocrinologymedicine.anatomical_structurechemistryBiochemistryLiverOrgan SpecificityCarnitine biosynthesisMolecular Medicinemedicine.drugHormonedescription
The carnitine system plays a key role in beta-oxidation of long-chain fatty acids by permitting their transport into the mitochondrial matrix. The effects of hypothyroidism and hyperthyroidism were studied on gamma-butyrobetaine hydroxylase (BBH), the enzyme responsible for carnitine biosynthesis in the rat. In rat liver, BBH activity was decreased in the hypothyroid state and increased in hyperthyroid animals. The modifications in BBH activity correlated with changes in the enzyme Vmax values. These changes were shown to be related to hepatic BBH mRNA abundance. Thyroid hormones are known to interact with lipid metabolism, in particular by increasing long-chain fatty acid oxidation through activation of carnitine-dependent fatty acid import into mitochondria. Our study showed that thyroid hormones also increased carnitine bioavailability.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2002-04-20 | Cellular and molecular life sciences : CMLS |